uu.seUppsala University Publications
Change search
Link to record
Permanent link

Direct link
BETA
Alternative names
Publications (10 of 442) Show all publications
Panezai, J., Altamash, M., Engström, P.-E. & Larsson, A. (2020). Association of Glycated Proteins with Inflammatory Proteins and Periodontal Disease Parameters.. Journal of Diabetes Research, 2020, Article ID 6450742.
Open this publication in new window or tab >>Association of Glycated Proteins with Inflammatory Proteins and Periodontal Disease Parameters.
2020 (English)In: Journal of Diabetes Research, ISSN 2314-6745, E-ISSN 2314-6753, Vol. 2020, article id 6450742Article in journal (Refereed) Published
Abstract [en]

Periodontitis is a chronic inflammatory condition that may contribute to diabetogenesis. The aim was to investigate the levels of glycated proteins and their correlation with periodontal and systemic inflammation. Fifty-one patients with periodontitis and 20 healthy subjects underwent probing pocket depth (PPD) measurements. PPD total and PPD disease with and without tooth adjustment were used as continuous indices. Marginal bone loss (MBL) for mandibular premolars and molars was measured digitally. Body mass index (BMI) and waist circumference (WC) were also analyzed. Glycated hemoglobin (HbA1c) and fructosamine (FrAm) levels were measured in all subjects. A multiplex proximity extension assay (PEA) was used to analyze the serum samples for simultaneous measurement of 92 proteins. Both HbA1c and FrAm inversely correlated with IL-10, FGF-21, MCP-1, and TNF beta amongst 16 proteins. HbA1c correlated directly with OPG. Parameters of disease severity were consistently significant for HbA1c. Adjusted PPD total and number of missing teeth were increased in diabetes whereas levels of RANKL and RANKL to OPG ratio were the highest in nondiabetic periodontitis patients. Hyperglycemic conditions in periodontitis patients are associated with reduced levels of anti-inflammatory proteins as well as dysregulated bone resorption.

National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-403677 (URN)10.1155/2020/6450742 (DOI)000508362700001 ()31998807 (PubMedID)
Available from: 2020-02-02 Created: 2020-02-02 Last updated: 2020-02-26Bibliographically approved
Fellström, B., Helmersson-Karlqvist, J., Lind, L., Soveri, I., Wu, P.-H., Thulin, M., . . . Larsson, A. (2020). Associations Between Apolipoprotein A1, High-Density Lipoprotein Cholesterol, and Urinary Cytokine Levels in Elderly Males and Females. Journal of Interferon and Cytokine Research, 40(2), 71-74
Open this publication in new window or tab >>Associations Between Apolipoprotein A1, High-Density Lipoprotein Cholesterol, and Urinary Cytokine Levels in Elderly Males and Females
Show others...
2020 (English)In: Journal of Interferon and Cytokine Research, ISSN 1079-9907, E-ISSN 1557-7465, Vol. 40, no 2, p. 71-74Article in journal (Refereed) Published
Abstract [en]

There exists a close relationship between cardiovascular diseases and chronic kidney disease. Apolipoprotein A1 and high-density lipoprotein (HDL) cholesterol are widely used as cardiovascular risk markers but they also have anti-inflammatory properties. The aim of this study was to investigate any associations between HDL levels and cytokine levels in urine. We randomly selected 90 urine samples from the Prospective Investigation of the Vasculature in Uppsala Seniors Study (41 males and 49 females). The samples were analyzed with 2 multiplex assays, Multiplex Inflammation I and Cardiovascular II kits (Olink Bioscience, Uppsala, Sweden). We analyzed the correlations between 158 cytokines in urine with apolipoprotein A1, HDL cholesterol, apolipoprotein B, and low-density lipoprotein cholesterol. There were strong correlations for apolipoprotein A1 and HDL cholesterol with individual cytokines. After adjustment for multiplicity testing, there were 33 significant correlations between apolipoprotein A1 and cytokine levels and 14 of these were also significantly correlated with HDL cholesterol. The strongest associations were observed for IL-1 alpha, SPON2, RAGE, PAR-1, TRAIL-R2, IL-4RA, TNFRSF11A, and SCF. A total of 28 out of 33 correlations were negative, indicating a negative relationship between apolipoprotein A1 and urinary cytokines. The study shows a negative correlation between apolipoprotein A1 and HDL cholesterol and urinary cytokine levels. The finding is in agreement with the anti-inflammatory properties of HDL.

Keywords
HDL cholesterol, apolipoprotein A1, cytokines, multiplex assays, urine
National Category
Clinical Laboratory Medicine
Identifiers
urn:nbn:se:uu:diva-394993 (URN)10.1089/jir.2019.0074 (DOI)000510520300001 ()31599692 (PubMedID)
Available from: 2019-10-11 Created: 2019-10-11 Last updated: 2020-03-20Bibliographically approved
Zamaratskaia, G., Mhd Omar, N. A., Brunius, C., Hallmans, G., Johansson, J.-E., Andersson, S.-O., . . . Landberg, R. (2020). Consumption of whole grain/bran rye instead of refined wheat decrease concentrations of TNF-R2, e-selectin, and endostatin in an exploratory study in men with prostate cancer. Clinical Nutrition, 39(1), 159-165
Open this publication in new window or tab >>Consumption of whole grain/bran rye instead of refined wheat decrease concentrations of TNF-R2, e-selectin, and endostatin in an exploratory study in men with prostate cancer
Show others...
2020 (English)In: Clinical Nutrition, ISSN 0261-5614, E-ISSN 1532-1983, Vol. 39, no 1, p. 159-165Article in journal (Refereed) Published
Abstract [en]

BACKGROUND & AIMS: Rye consumption has shown beneficial effects on prostate cancer tumors, as indicated by slower initial tumor growth in animal models and lowering of prostate-specific antigen (PSA) in humans. This study evaluated the effects of whole grain/bran rye consumption on low-grade inflammation and endothelial function biomarkers in men with prostate cancer.

METHODS: Seventeen men with untreated, low-grade prostate cancer consumed 485 g rye whole grain and bran products (RP) per day or refined wheat products with added cellulose (WP) in a randomized crossover design. Fasting blood samples were taken before and after 2, 4, and 6 weeks of treatment.

RESULTS: Concentrations of tumor nuclear factor-receptor 2 (TNF-R2), e-selectin, and endostatin were significantly lower after consumption of the RP diet compared with WP (p < 0.05). Cathepsin S concentration was positively correlated to TNF-R2 and endostatin concentrations across all occasions. Strong correlations were consistently found between intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) and between interleukin-6 (IL-6) and interleukin-1 receptor antagonist (IL-1RA). No effect of intervention was found in 92 inflammation-related protein biomarkers measured in a proximity extension assay.

CONCLUSIONS: RP diet lowered TNF-R2, e-selectin, and endostatin, compared with WP in men with prostate cancer. These effects were accompanied by a reduction in PSA.

Place, publisher, year, edition, pages
Elsevier, 2020
Keywords
Endothelial function markers, Low-grade inflammatory markers, Plasma, Prostate cancer, Refined wheat, Whole grain/bran rye
National Category
Nutrition and Dietetics
Identifiers
urn:nbn:se:uu:diva-377643 (URN)10.1016/j.clnu.2019.01.007 (DOI)000510526200018 ()30685298 (PubMedID)
Funder
Swedish Research CouncilSwedish Research Council Formas
Available from: 2019-02-23 Created: 2019-02-23 Last updated: 2020-03-30Bibliographically approved
Carlsson, A. C., Wessman, T., Larsson, A., Leijonberg, G., Tofik, R., Ärnlöv, J., . . . Ruge, T. (2020). Endostatin predicts mortality in patients with acute dyspnea: A cohort study of patients seeking care in emergency departments. Clinical Biochemistry, 75, 35-39
Open this publication in new window or tab >>Endostatin predicts mortality in patients with acute dyspnea: A cohort study of patients seeking care in emergency departments
Show others...
2020 (English)In: Clinical Biochemistry, ISSN 0009-9120, E-ISSN 1873-2933, Vol. 75, p. 35-39Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Increased levels of circulating endostatin predicts cardiovascular morbidity and impaired kidney function in the general population. The utility of endostatin as a risk marker for mortality in the emergency department (ED) has not been reported.

AIM: Our main aim was to study the association between plasma endostatin and 90-day mortality in an unselected cohort of patients admitted to the ED for acute dyspnea.

Design: Circulating endostatin was analyzed in plasma from 1710 adults and related to 90-day mortality in Cox proportional hazard models adjusted for age, sex, body mass index, oxygen saturation, respiratory rate, body temperature, C-reactive protein, lactate, creatinine and medical priority according to the Medical Emergency Triage and Treatment System-Adult score (METTS-A). The predictive value of endostatin for mortality was evaluated with receiver operating characteristic (ROC) analysis and compared with the clinical triage scoring system and age.

RESULTS: Each one standard deviation increment of endostatin was associated with a HR of 2.12 (95 % CI 1.31-3.44 p< 0.01) for 90-day mortality after full adjustment. Levels of endostatin were significantly increased in the group of patients with highest METTS-A (p<0.001). When tested for the outcome 90-day mortality, the area under the ROC curve (AUC) was 0.616 for METTS-A, 0.701 for endostatin, 0.708 for METTS -A and age and 0.738 for METTS-A, age and levels of endostatin.

CONCLUSIONS: In an unselected cohort of patients admitted to the ED with acute dyspnea, endostatin had a string association to 90-day mortality and improved prediction of 90-day mortality in the ED beyond the clinical triage scoring system and age with 3 %.

Keywords
Acute dyspnea, Cardiovascular, Emergency department, Endostatin, Epidemiology, METTS-A, Mortality
National Category
Respiratory Medicine and Allergy
Identifiers
urn:nbn:se:uu:diva-396317 (URN)10.1016/j.clinbiochem.2019.10.004 (DOI)000503447200006 ()31672650 (PubMedID)
Funder
Knut and Alice Wallenberg FoundationGöran Gustafsson Foundation for Research in Natural Sciences and MedicineSwedish Heart Lung FoundationSwedish Research CouncilNovo NordiskRegion Skåne
Available from: 2019-11-02 Created: 2019-11-02 Last updated: 2020-01-29Bibliographically approved
Nilsson, E., Kastrup, J., Sajadieh, A., Boje Jensen, G., Kjøller, E., Kolmos, H. J., . . . Carlsson, A. C. (2020). Pregnancy Associated Plasma Protein-A as a Cardiovascular Risk Marker in Patients with Stable Coronary Heart Disease During 10 Years Follow-Up: A CLARICOR Trial Sub-Study. Journal of clinical medicine, 9(1), Article ID 265.
Open this publication in new window or tab >>Pregnancy Associated Plasma Protein-A as a Cardiovascular Risk Marker in Patients with Stable Coronary Heart Disease During 10 Years Follow-Up: A CLARICOR Trial Sub-Study
Show others...
2020 (English)In: Journal of clinical medicine, ISSN 2077-0383, Vol. 9, no 1, article id 265Article in journal (Refereed) Published
Abstract [en]

Elevated pregnancy-associated plasma protein A (PAPP-A) is associated with mortality in acute coronary syndromes. Few studies have assessed PAPP-A in stable coronary artery disease (CAD) and results are conflicting. We assessed the 10-year prognostic relevance of PAPP-A levels in stable CAD. The CLARICOR trial was a randomized controlled clinical trial including outpatients with stable CAD, randomized to clarithromycin versus placebo. The placebo group constituted our discovery cohort (n = 1.996) and the clarithromycin group the replication cohort (n = 1.975). The composite primary outcome was first occurrence of cardiovascular event or death. In the discovery cohort, incidence rates (IR) for the composite outcome were higher in those with elevated PAPP-A (IR 12.72, 95% Confidence Interval (CI) 11.0-14.7 events/100 years) compared to lower PAPP-A (IR 8.78, 8.25-9.34), with comparable results in the replication cohort. Elevated PAPP-A was associated with increased risk of the composite outcome in both cohorts (discovery Hazard Ratio (HR) 1.45, 95% CI 1.24-1.70; replication HR 1.29, 95% CI 1.10-1.52). In models adjusted for established risk factors, these trends were attenuated. Elevated PAPP-A was associated with higher all-cause mortality in both cohorts. We conclude that elevated PAPP-A levels are associated with increased long-term mortality in stable CAD, but do not improve long-term prediction of death or cardiovascular events when added to established predictors.

Keywords
biomarkers, cohort studies, coronary artery disease, pregnancy-associated plasma protein-A
National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:uu:diva-403679 (URN)10.3390/jcm9010265 (DOI)000515388400265 ()31963719 (PubMedID)
Available from: 2020-02-02 Created: 2020-02-02 Last updated: 2020-03-27Bibliographically approved
Abujrais, S., Olovsson, M., Ahnoff, M., Rasmusson, A., Larsson, A., Åkerfeldt, T. & Kultima, K. (2019). A sensitive method detecting trace levels of levonorgestrel using LC-HRMS.. Contraception, 100(3), 247-249
Open this publication in new window or tab >>A sensitive method detecting trace levels of levonorgestrel using LC-HRMS.
Show others...
2019 (English)In: Contraception, ISSN 0010-7824, E-ISSN 1879-0518, Vol. 100, no 3, p. 247-249Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE: To develop a high resolution mass spectrometry (HRMS) method to quantify levonorgestrel (LNG) in serum.

STUDY DESIGN: Levonorgestrel was extracted using solid phase extraction and measured using liquid chromatography (LC) HRMS.

RESULTS: Low limit of quantification (LLOQ) was 25pg/mL and low limit of detection (LLOD) was 12.5pg/mL. Precision and accuracy bias were<10%. LNG in serum samples from Mirena® users ranged between 37 to 219pg/mL (n=12). In eight out of 22 patients with suspected intrauterine device (IUD) expulsion LNG was detected (26 to 1272pg/mL).

CONCLUSION: A sensitive, fast and simple LC-HRMS method was developed to detect trace levels of LNG.

Keywords
High resolution mass spectrometry, Intrauterine device, Liquid chromatography, Lower limit of quantification, Solid phase extraction
National Category
Obstetrics, Gynecology and Reproductive Medicine
Identifiers
urn:nbn:se:uu:diva-388593 (URN)10.1016/j.contraception.2019.06.001 (DOI)000483452100015 ()31216423 (PubMedID)
Available from: 2019-07-02 Created: 2019-07-02 Last updated: 2019-10-17Bibliographically approved
Nordin, G., Ekvall, S., Kristoffersson, C., Jonsson, A.-S., Bäck, S.-E., Rollborn, N. & Larsson, A. (2019). Accuracy of determination of the glomerular filtration marker iohexol by European laboratories as monitored by external quality assessment. Clinical Chemistry and Laboratory Medicine, 57(7), 1006-1011
Open this publication in new window or tab >>Accuracy of determination of the glomerular filtration marker iohexol by European laboratories as monitored by external quality assessment
Show others...
2019 (English)In: Clinical Chemistry and Laboratory Medicine, ISSN 1434-6621, E-ISSN 1437-4331, Vol. 57, no 7, p. 1006-1011Article in journal (Refereed) Published
Abstract [en]

Background Glomerular filtration is the most important kidney function. The most accurate glomerular filtration rate (GFR) estimates are based on the clearance of exogenous filtration markers. Of these, iohexol is the only exogenous marker that is included in an external quality assessment (EQA) scheme. The aim of the present study was to evaluate the performance of the European laboratories participating in Equalis' EQA scheme for iohexol. Methods Weighed amounts of iohexol (Omnipaque) were added to plasma samples and distributed to laboratories participating in the EQA scheme for iohexol. All laboratories performed the assays in a blinded fashion. Results The number of participating laboratories varied between 27 and 34 during the study period. Iohexol was determined by HPLC in 77% of the laboratories and by UPLC/MS/MS methods in 15% of the laboratories. The mean interlaboratory coefficient of variation was 4.7% for the HPLC methods and 6.4% for the UPLC/MS/MS methods. The mean bias between calculated and measured iohexol values was -1.3 mg/L (95% confidence interval ±0.3) during the first part of the study period and 0.1 mg/L (±0.3) during the later part. Conclusions The low interlaboratory variation demonstrates that iohexol can be measured reliably by many laboratories and supports the use of iohexol as a GFR marker when there is a need for high quality GFR measurements.

Place, publisher, year, edition, pages
Walter de Gruyter, 2019
Keywords
GFR, external quality assessment scheme, glomerular filtration rate, iohexol
National Category
Clinical Laboratory Medicine
Identifiers
urn:nbn:se:uu:diva-383248 (URN)10.1515/cclm-2018-1175 (DOI)000470676100019 ()31075079 (PubMedID)
Available from: 2019-05-11 Created: 2019-05-11 Last updated: 2019-06-26Bibliographically approved
Chang, A. R., Grams, M. E., Ballew, S. H., Bilo, H., Correa, A., Evans, M., . . . Woodward, M. (2019). Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium. BMJ. British Medical Journal, 364, Article ID k5301.
Open this publication in new window or tab >>Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium
Show others...
2019 (English)In: BMJ. British Medical Journal, E-ISSN 1756-1833, Vol. 364, article id k5301Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE: To evaluate the associations between adiposity measures (body mass index, waist circumference, and waist-to-height ratio) with decline in glomerular filtration rate (GFR) and with all cause mortality.

DESIGN: Individual participant data meta-analysis.

SETTING: Cohorts from 40 countries with data collected between 1970 and 2017.

PARTICIPANTS: Adults in 39 general population cohorts (n=5 459 014), of which 21 (n=594 496) had data on waist circumference; six cohorts with high cardiovascular risk (n=84 417); and 18 cohorts with chronic kidney disease (n=91 607).

MAIN OUTCOME MEASURES: GFR decline (estimated GFR decline ≥40%, initiation of kidney replacement therapy or estimated GFR <10 mL/min/1.73 m2) and all cause mortality.

RESULTS: Over a mean follow-up of eight years, 246 607 (5.6%) individuals in the general population cohorts had GFR decline (18 118 (0.4%) end stage kidney disease events) and 782 329 (14.7%) died. Adjusting for age, sex, race, and current smoking, the hazard ratios for GFR decline comparing body mass indices 30, 35, and 40 with body mass index 25 were 1.18 (95% confidence interval 1.09 to 1.27), 1.69 (1.51 to 1.89), and 2.02 (1.80 to 2.27), respectively. Results were similar in all subgroups of estimated GFR. Associations weakened after adjustment for additional comorbidities, with respective hazard ratios of 1.03 (0.95 to 1.11), 1.28 (1.14 to 1.44), and 1.46 (1.28 to 1.67). The association between body mass index and death was J shaped, with the lowest risk at body mass index of 25. In the cohorts with high cardiovascular risk and chronic kidney disease (mean follow-up of six and four years, respectively), risk associations between higher body mass index and GFR decline were weaker than in the general population, and the association between body mass index and death was also J shaped, with the lowest risk between body mass index 25 and 30. In all cohort types, associations between higher waist circumference and higher waist-to-height ratio with GFR decline were similar to that of body mass index; however, increased risk of death was not associated with lower waist circumference or waist-to-height ratio, as was seen with body mass index.

CONCLUSIONS: Elevated body mass index, waist circumference, and waist-to-height ratio are independent risk factors for GFR decline and death in individuals who have normal or reduced levels of estimated GFR.

National Category
Urology and Nephrology
Identifiers
urn:nbn:se:uu:diva-373654 (URN)10.1136/bmj.k5301 (DOI)000455770800012 ()30630856 (PubMedID)
Note

Anders Larsson, Lars Lannfelt and Johan Ärnlöv are collaborators in the CKD Prognosis Consortium (CKD-PC).

Available from: 2019-01-17 Created: 2019-01-17 Last updated: 2019-04-02Bibliographically approved
Ridefelt, P., Hagström, E., Svensson, M. K., Åkerfeldt, T. & Larsson, A. (2019). Age- and sex-specific reference values for non-HDL cholesterol and remnant cholesterol derived from the Nordic Reference Interval Project (NORIP). Scandinavian Journal of Clinical and Laboratory Investigation, 79(1-2), 39-42
Open this publication in new window or tab >>Age- and sex-specific reference values for non-HDL cholesterol and remnant cholesterol derived from the Nordic Reference Interval Project (NORIP)
Show others...
2019 (English)In: Scandinavian Journal of Clinical and Laboratory Investigation, ISSN 0036-5513, E-ISSN 1502-7686, Vol. 79, no 1-2, p. 39-42Article in journal (Refereed) Published
Abstract [en]

OBJECTIVES: Non-HDL-cholesterol (non-HDL-C) has been reported to be a better marker of cardiovascular risk than LDL-cholesterol (LDL-C) especially in individuals with high triglyceride values. Further, levels of remnant cholesterol have been suggested to in part explain residual risk not captured with LDL-C. The aim of the present study was to define reference values for non-HDL-C and remnant cholesterol based on data from the Nordic Reference Interval Project (NORIP).

METHODS: We analyzed the test results for total cholesterol, HDL-cholesterol and triglycerides from 1392 healthy females and 1236 healthy males. Non-HDL-C was calculated as measured total cholesterol minus measured HDL-cholesterol. Remnant cholesterol was calculated using the Friedewald equation for LDL-C: measured total cholesterol minus measured HDL-cholesterol and minus calculated LDL-cholesterol. The 2.5th and 97.5th percentiles for these markers were calculated according to the International Federation of Clinical Chemistry guidelines on the statistical treatment of reference values.

RESULTS: Age (18-<30, 30-49 and ≥50 years) and sex-specific reference intervals were calculated for non-HDL-cholesterol and remnant-cholesterol. Levels of non-HDL-C and remnant cholesterol differed between sex and age strata.

CONCLUSIONS: Age- and sex-specific reference intervals should be used for the triglyceride rich lipid variables non-HDL-C and remnant cholesterol. Since these markers may add information on risk burden beyond LDL-C, our hope is that these reference intervals will aid the introduction of automatic reporting of non-HDL-C by hospital laboratories.

Place, publisher, year, edition, pages
Taylor & Francis Group, 2019
Keywords
HDL-cholesterol, Reference values, non-HDL-cholesterol, remnant cholesterol, triglyceride-rich particles
National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:uu:diva-373651 (URN)10.1080/00365513.2018.1550809 (DOI)000508354200006 ()30638091 (PubMedID)
Available from: 2019-01-15 Created: 2019-01-15 Last updated: 2020-03-05Bibliographically approved
Govorov, I., Bremme, K., Larsson, A., Holmström, M., Komlichenko, E., Chaireti, R. & Mints, M. (2019). Blood inflammatory and endothelial markers in women with von Willebrand disease. PLoS ONE, 14(1), Article ID e0210544.
Open this publication in new window or tab >>Blood inflammatory and endothelial markers in women with von Willebrand disease
Show others...
2019 (English)In: PLoS ONE, ISSN 1932-6203, E-ISSN 1932-6203, Vol. 14, no 1, article id e0210544Article in journal (Refereed) Published
Abstract [en]

Introduction: VWD-affected females often experience menorrhagia. Periodical fluctuations of the sex steroids during the menstrual cycle cause changes both in the coagulation and immune system. The aim of the current study was to assess the changes in selected inflammatory and endothelial markers in women with VWD during two phases of the menstrual cycle (follicular and luteal) and to compare it with corresponding data from healthy controls.

Materials and methods: The study group included 12 VWD-affected females with regular menstrual cycle, with none of them being prescribed hormone treatment. They were not pregnant or breastfeeding. The control group consisted of 102 healthy females, matched for age and BMI.

Results: Within the VWD group, endostatin was higher during the follicular phase, compared to the luteal phase, although the difference was not significant (p = 0.062). sICAM-1 and IL-6 were higher in VWD-affected females, compared to the controls, sVCAM-1, cathepsin S and sP-selectin were lower (p<0.003 for all cases). The pattern was constant throughout the menstrual cycle.

Conclusions: Higher levels of endostatin during early follicular phase could potentially predispose women with VWD to the development of heavy menstrual bleeding, due to antiangiogenic properties and ability to suppress several coagulation factors. Lower p-selectin levels in VWD group, compared to controls, may also contribute to the bleeding tendency. Changes in other proteins, involved in angiogenesis are hypothetically related to the formation of angiodysplasia—common complication of VWF deficiency. The latter statement requires confirmation in larger studies.

National Category
Obstetrics, Gynecology and Reproductive Medicine
Identifiers
urn:nbn:se:uu:diva-373652 (URN)10.1371/journal.pone.0210544 (DOI)000455483000105 ()30629692 (PubMedID)
Available from: 2019-01-15 Created: 2019-01-15 Last updated: 2019-02-05Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0003-3161-0402

Search in DiVA

Show all publications